Casper Breum

Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel.

Asante Solutions, Inc. operated as a medical device company that focuses on the management of diabetes for patients and healthcare practitioners. The firm offered Asante Snap insulin pump system (Snap system), a pump for individuals starting insulin pump therapy and for existing pumpers. The company was founded by James L. Peterson in 2006 and was headquartered in Sunnyvale, CA.

Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark.

Biom'Up SA engages in the development of hemostatic product composed of patent-protected biopolymers. Its products include Hemoblast Bellows and Hemosnow. The company was founded by Patricia Forest, Sylvain Picot and Christian Gagnieu on February 21, 2005 and is headquartered in Lyon, France.

Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.

Lundbeckfond Invest A/S (Lundbeckfond Invest) is the investment management subsidiary of the Lundbeck Foundation in Denmark. Established in 1999, the firm is based in Copenhagen and manages the Lundbeck Foundation's investments, aiming for long-term, stable returns with moderate risk, such that the Foundation's net capital is not jeopardized and the Foundation is able to meet its commitments in terms of awarding grants and of laying a capital base for its subsidiaries.

VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.